Integrative reverse vaccinology and computational modeling for the rational design of a broadly immunogenic multi-epitope vaccine against Marburg virus infection.

Structure-Guided Immunoinformatics for the Rational Design of a Multi-Epitope Vaccine Against Batai Orthobunyavirus

This study presents a structurally optimized and validated multiepitope vaccine candidate against the emerging Batai orthobunyavirus, identifying a promising vaccine candidate for further investigation; however, its immunogenicity, safety, and protective efficacy before further vaccine development can be considered.

Harnessing reverse vaccinology for the design and validation of mRNA vaccine targeting the glycoprotein of human metapneumovirus (HMPV)

The two proposed multi-epitope mRNA vaccine constructs showed promising immunogenic, safety, and structural properties in silico, highlighting their potential as candidate vaccines against HMPV.

Design of a Novel Multi-Epitope mRNA Vaccine against Marburg Virus using Reverse Vaccinology

In silico cloning validated the capacity for effective expression in E. coli and secondary structure revealed that the mRNA vaccine was thermodynamically stable, which may contribute to the development of an experimental MARV vaccine.

Integrative immunoinformatics and structural modeling for the rational design of a multi-epitope vaccine candidate against human cytomegalovirus

The results highlight the potential of the proposed multi-epitope construct as a promising vaccine candidate against HCMV, however, experimental validation is essential to confirm its immunogenicity, safety, and translational applicability.

In Silico design and evaluation of a multi-epitope vaccine candidate against Toxoplasma gondii for humans

The rationally designed multi-epitope vaccine demonstrates robust theoretical potential to elicit comprehensive, long-lasting immunity in humans, although its safety and effectiveness require additional experimental validation.

Immunoinformatics-guided design of a conserved multi-epitope vaccine candidate against pathogenic human coronaviruses.